Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol-Reference-Cited by-同舟云学术

Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol

Published:2000-04 Issue:1-3 Volume:144 Page:221-228
ISSN:0300-483X
Container-title:Toxicology
language:en
Short-container-title:Toxicology

Author:

Aigner Achim,Hsieh Susie S,Malerczyk Claudius,Czubayko Frank

Publisher

Elsevier BV

Subject

Toxicology

Reference26 articles.

1. Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human malignancies;Alimandi;Oncogene,1995

2. The erbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions;Alroy;FEBS Letts,1997

3. Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu over-expressing human breast cancer xenografts;Baselga;Cancer Res.,1998

4. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation;Czubayko;Gene Ther.,1997

5. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth;Czubayko;J. Biol. Chem.,1994

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies;Molecular Therapy - Oncolytics;2023-03

2. Chemotherapy Resistance in Advanced Ovarian Cancer Patients;Biomarkers in Cancer;2019-01

3. Antrodia salmonea ‐induced oxidative stress abrogates HER‐2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells;Journal of Cellular Physiology;2018-08-26

4. A Combination Therapy with Baicalein and Taxol Promotes Mitochondria-Mediated Cell Apoptosis: Involving in Akt/β-Catenin Signaling Pathway;DNA and Cell Biology;2016-11

5. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models;BMC Cancer;2016-03-10